Retatrutide

Weight Loss · Metabolism Subcutaneous Injectable

Retatrutide is a next-generation triple agonist targeting GLP-1, GIP, and glucagon receptors. Clinical trials have shown weight-loss magnitudes exceeding Tirzepatide — making it a leading option for clients who have plateaued on existing GLP-1 therapy or face refractory metabolic dysfunction. Available through research-guided protocols.

Best for: Clients who have plateaued on other GLP-1 therapies, refractory metabolic dysfunction.

Lab-guided protocolsPersonalized dosingProvider-led oversightIn-clinic & telehealth Lab-guided protocolsPersonalized dosingProvider-led oversightIn-clinic & telehealth

The questions, answered.

  • Highest weight-loss magnitude in current research — often exceeding 20%.
  • Triple-receptor coverage for layered metabolic benefit.
  • Glucagon agonism increases energy expenditure alongside appetite suppression.
  • Improves insulin sensitivity at the receptor and tissue levels.
  • Significant visceral fat reduction.
  • Promising for clients who have plateaued on Tirzepatide or Semaglutide.
  • Triple receptor agonism: GLP-1 + GIP + glucagon.
  • Increased energy expenditure from glucagon activity.
  • Central and peripheral appetite suppression.
  • Improved adipose tissue metabolism.
  • Weeks 1–2: GI acclimation; early weight loss accelerates past usual GLP-1 pace.
  • Weeks 4–6: Rapid steady-state weight loss; metabolic markers improve.
  • Weeks 8–12: Substantial body composition shifts; maintenance dosing planned.
  • Nausea, GI symptoms similar to other GLP-1s — manageable with titration.
  • Heart rate elevation at higher doses — monitored with labs.
  • Fatigue early in protocol.
  • Injection-site reactions.
  • Slow titration — start low, climb gradually.
  • Track HR and BP at home alongside provider visits.
  • Prioritize protein and strength training to preserve muscle.
  • Stay hydrated and electrolyte-balanced.
  • Personal or family history of medullary thyroid carcinoma or MEN-2.
  • Active pancreatitis.
  • Pregnancy or breastfeeding.
  • Investigational status: requires careful informed consent.
Important Note The FDA's position on peptides continues to evolve. Availability of specific compounds may change, and not all peptides discussed are currently offered at every visit. Book a consultation with our provider team to discuss your goals, current options, and what's appropriate for you.

Layered with intention.

— Begin

Precision protocols.
Designed around you.

Every TAI peptide protocol is lab-guided and provider-led. Start with biomarkers, design around your goals, refine at intervals. Available in-clinic and via telehealth.

Book Consult Membership pricing